Baba Keiichiro, Sumiya Taisuke, Saito Takashi, Murakami Motohiro, Sakurai Hideyuki
Radiation Oncology, University of Tsukuba Hospital, Tsukuba, JPN.
Cureus. 2025 May 5;17(5):e83541. doi: 10.7759/cureus.83541. eCollection 2025 May.
Lenvatinib and radiotherapy, including brachytherapy, are treatment options for patients with endometrial cancer. However, it is unclear if lenvatinib can induce ulceration and necrosis in patients who have previously received brachytherapy. Here, we describe the case of a 63-year-old woman with endometrial cancer who developed postoperative vaginal wall recurrence and received brachytherapy. One year later, she was given lenvatinib, and two months later, she developed radiation-induced vaginal necrosis, which rapidly progressed to rectovaginal fistula. This case shows that physicians should be aware of the possibility of vaginal necrosis in the administration of lenvatinib to patients who have previously undergone radiotherapy including brachytherapy for the uterus or vagina.
乐伐替尼和放射治疗，包括近距离放射治疗，是子宫内膜癌患者的治疗选择。然而，乐伐替尼是否会在先前接受过近距离放射治疗的患者中诱发溃疡和坏死尚不清楚。在此，我们描述了一名63岁子宫内膜癌女性患者的病例，该患者术后出现阴道壁复发并接受了近距离放射治疗。一年后，她接受了乐伐替尼治疗，两个月后，出现了放射性阴道坏死，并迅速发展为直肠阴道瘘。该病例表明，医生在给先前接受过子宫或阴道放射治疗（包括近距离放射治疗）的患者使用乐伐替尼时，应意识到发生阴道坏死的可能性。
